Cancer in Belgium

IARC estimates 80,019 new cancer cases and 28,692 cancer deaths in Belgium in 2024; the commonest new cancers are breast, prostate and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 916 trials with a site there, 24 institutions, 13 companies, 30 people and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

80,019

all cancers

Deaths

28,692

all cancers

Incidence rate

314.0

per 100,000, age-standardised

Mortality rate

86.5

per 100,000, age-standardised

Cumulative risk

30.6%

of a cancer by age 74

Population

11,738,768

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Breast	10,928	98.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	10,436	81.0	Prostate cancer
Trachea, bronchus and lung	8,859	33.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	7,258	25.4	Colorectal cancer
Melanoma of skin	4,300	21.3	Melanoma
Bladder	4,172	13.7	Bladder & urothelial cancer
Non-Hodgkin lymphoma	2,656	10.6	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Pancreas	2,233	7.8	Pancreatic ductal adenocarcinoma
Leukaemia	2,033	9.3	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Kidney	1,992	7.9	Renal cell carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	5,992	19.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	3,087	8.5	Colorectal cancer
Breast	2,258	13.0	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	2,088	6.4	Pancreatic ductal adenocarcinoma
Prostate	1,984	10.0	Prostate cancer
Liver and intrahepatic bile ducts	1,225	3.8	Hepatocellular carcinoma
Leukaemia	1,136	3.3	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Bladder	1,038	2.5	Bladder & urothelial cancer
Oesophagus	899	3.0	Oesophageal cancer
Non-Hodgkin lymphoma	824	2.2	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Belgium”, in Western Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

916 trials in OnCo · 263 recruiting overall

916 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248	Phase 3	Recruiting	Merck Sharp & Dohme LLC	219	2026-10-07
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer NCT06072781	Phase 3	Recruiting	Verastem, Inc.	106	2026-10-07
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Phase 3	Recruiting	Eli Lilly and Company	416	2026-10-07
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer NCT07525206	Phase 3	Recruiting	AbbVie	85	2026-10-07
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa NCT06091865	Phase 3	Recruiting	Regeneron Pharmaceuticals	194	2026-10-07
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant NCT06149286	Phase 3	Recruiting	Regeneron Pharmaceuticals	171	2026-10-07
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re NCT05730036	Phase 3	Recruiting	Regeneron Pharmaceuticals	159	2026-10-07
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati NCT07195695	Phase 3	Recruiting	Boehringer Ingelheim	202	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML NCT07007312	Phase 3	Recruiting	Kura Oncology, Inc.	122	2026-10-07
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc NCT07216703	Phase 3	Recruiting	Merck Sharp & Dohme LLC	180	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) NCT07419295	Phase 3	Recruiting	Merck Sharp & Dohme LLC	104	2026-10-06
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip NCT06793215	Phase 3	Recruiting	Hoffmann-La Roche	288	2026-10-06
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par NCT05789082	Phase 1/2	Recruiting	Hoffmann-La Roche	71	2026-10-06
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680	Phase 2	Recruiting	Bristol-Myers Squibb	58	2026-10-06
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) NCT07630974	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	29	2026-10-06
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	64	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult NCT07059845	Phase 2	Recruiting	AbbVie	85	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy NCT06091254	Phase 3	Recruiting	Regeneron Pharmaceuticals	190	2026-10-06
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164	Phase 3	Recruiting	Merck Sharp & Dohme LLC	54	2026-10-06
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NCT06216301	Phase 3	Recruiting	NovoCure GmbH	104	2026-10-06
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer NCT07228832	Phase 3	Recruiting	Summit Therapeutics	236	2026-10-06

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Belgium, captured 2026-10-07 to 2026-10-10. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Belgium is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

24 institutions

ACCELERATE Antwerp University Hospital (UZA)Association of European Cancer Leagues AZ Groeninge Kortrijk Cancer Centre Belgian Society of Psychosocial Oncology Brussels Cancer Centre (UZ Brussel)Cancer Patients Europe CCI4EU: Comprehensive Cancer Infrastructures 4 Europe (EU Cancer Mission)Digestive Cancers Europe EU Mission on Cancer (Horizon Europe)Europa Uomo European Cancer Organisation European Society for Radiotherapy and Oncology European Society of Surgical Oncology Foundation against Cancer Ghent University Hospital / Cancer Research Institute Ghent Institut Jules Bordet King Albert II Cancer Institute, Cliniques universitaires Saint-Luc Kom op tegen Kanker Myeloma Patients Europe Organisation of European Cancer Institutes SIOP Europe (European Society for Paediatric Oncology)UZ Leuven / Leuven Cancer Institute World Bladder Cancer Patient Coalition

13 companies

argenx Biocartis Breast International Group (BIG)EORTC Galapagos IBA (Ion Beam Applications)InhaTarget Therapeutics IRE (Institut national des Radioéléments)OncoDNA PanTera Precirix Trasis UCB

30 people

People whose main affiliation in OnCo is an institution or company in Belgium.

Screening, vaccination and law

Term

Colorectal cancer screening programme in Belgium

Belgium runs a national colorectal cancer screening programme started in 2009, offering faecal immunochemical test (FIT) and colonoscopy, as recorded by IARC's CanScreen5 survey (2016).

Approvals

Belgium is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

From the country research ranking

Research funders: Fondation contre le Cancer / Kom op tegen Kanker; FWO / FNRS.
Named in the ranking: EORTC headquarters (Brussels).

From the country ranking's hand-curated row; follow its source before relying on a figure.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Belgium's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Belgium, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Belgium's own sources, beyond the programme records above.

A deep dive for Belgium is ranked 21 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today; Belgium fact sheet.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/be.json; every country: /api/v1/countries.json.